Evidence

The Changing Role of Gene-Expression Profiling in the Era of Deescalating Adjuvant Chemotherapy in Early-Stage Breast Cancer

June 17, 2019

PUBLICATION: Ann Surg Oncol (2019) 26: 3495. https://doi.org/10.1245/s10434-019-07511-8. AUTHORS: J.E.C. van Steenhoven, A. Kuijer, K. Schreuder, S.G. Elias, P.J. van Diest, E. van der Wall, S. Siesling, T. van Dalen SUMMARY: A Netherlands Cancer Registry study correlated the increased use of MammaPrint led to decreased chemotherapy use, especially for LN+ and younger women. Read more: Steenhoven et al_2019_Annals…

Read more

Pertuzumab/Trastuzumab/CT Versus Trastuzumab/CT Therapy for HER2+ Breast Cancer: Results from the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)

April 26, 2017

PUBLICATION: Ann Surg Oncol. 2017 Sep;24(9):2539-2546. doi: 10.1245/s10434-017-5863-x. AUTHORS: Peter Beitsch, MD; Pat Whitworth, MD; Paul Baron, MD; Michael C. Rotkis, MD; Angela M. Mislowsky, MD; Paul D. Richards, MD; Mary K. Murray, MD; James V. Pellicane, MD; Carrie L. Dul, MD; Charles H. Nash, MD; Lisette Stork-Sloots, MSc; Femke de Snoo, MD, PhD; Sarah Untch, BS;…

Read more

Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping

October 21, 2016

PUBLICATION: Annals of Surgical Oncology; March 2017, Volume 24, Issue 3; pp 669–675. AUTHORS: Pat Whitworth, Peter Beitsch, Angela Mislowsky, James V. Pellicane, Charles Nash, Mary Murray, Laura A. Lee, Carrie L. Dul, Michael Rotkis, Paul Baron, Lisette Stork-Sloots, Femke A. de Snoo, Jennifer Beatty ABSTRACT: Hormone receptor-positive (HR+) tumors have heterogeneous biology and present a challenge for…

Read more

Genomic Impact of Neoadjuvant Therapy on Breast Cancer: Incomplete Response is Associated with Altered Diagnostic Gene Signatures

July 6, 2016

PUBLICATION: Ann Surg Oncol (2016) 23: 3317. https://doi.org/10.1245/s10434-016-5329-6. AUTHORS: Peter Beitsch, Pat Whitworth, Paul Baron, James Pellicane, Tina Treece, Erin Yoder, Mark Gittleman, NBRST Investigators Group SUMMARY: This substudy showed that NAT significantly altered the genomic signature of the patient’s breast cancer compared with the patient’s pre-treatment genomic profile. These alterations occurred in a subtype-dependent manner, suggesting that…

Read more

Impact of Tumor Size on Probability of Pathologic Complete Response After Neoadjuvant Chemotherapy

May 1, 2016

PUBLICATION: Ann Surg Oncol (2016) 23: 1522. https://doi.org/10.1245/s10434-015-5030-1. AUTHORS: Paul Baron, Peter Beitsch, Danielle Boselli, James Symanowski, James V. Pellicane, Jennifer Beatty, Paul Richards, Angela Mislowsky, Charles Nash, Laura A. Lee, Mary Murray, Femke A. de Snoo, Lisette Stork-Sloots, Mark Gittleman, Stephanie Akbari, Pat Whitworth SUMMARY: We found that although size was correlated inversely with the frequency of…

Read more

Chemosensitivity Predicted by BluePrint 80-Gene Functional Subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)

August 7, 2014

PUBLICATION: Annals of Surgical Oncology; October 2014, Volume 21, Issue 10; pp 3261–3267. AUTHORS: Pat Whitworth, MD; Lisette Stork-Sloots, MSc; Femke A. de Snoo, MD, PhD; Paul Richards, MD; Michael Rotkis, MD; Jennifer Beatty, DO; Angela Mislowsky, MD; James V. Pellicane, MD; Bichlien Nguyen, MD; Laura Lee, MD; Charles Nash, MD; Mark Gittleman, MD; Stephanie Akbari, MD;…

Read more

Comparison of Molecular Subtyping with BluePrint, MammaPrint, and TargetPrint to Local Clinical Subtyping in Breast Cancer Patients

August 15, 2012

PUBLICATION: Ann Surg Oncol. 2012 Oct;19(10):3257-63. doi: 10.1245/s10434-012-2561-6. Epub 2012 Aug 15. AUTHORS: Nguyen B., Cusumano P.G., Deck K., Kerlin D., Garcia A.A., Barone J..L, Rivera E., Yao K., de Snoo F.A., van den Akker J., Stork-Sloots L., Generali D. SUMMARY: The concordance between BluePrint and IHC/FISH subtyping was 94% for the Luminal-type, 95% for the HER2-type, and…

Read more

Metastatic Potential of T1 Breast Cancer Can Be Predicted by the 70-gene MammaPrint Signature

May 1, 2010

PUBLICATION: Ann Surg Oncol. 2010 May;17(5):1406-13. doi: 10.1245/s10434-009-0902-x. Epub 2010 Jan 22. AUTHORS: Mook S., Knauer M., Bueno-de-Mesquita J.M., Retel V.P., Wesseling J., Linn S.C., Van’t Veer L.J., Rutgers E.J. SUMMARY: The 10-year distant metastasis-free (DMFS) and breast cancer specific survival (BCSS) probabilities were 87% (SE 2%) and 91% (SE 2%), respectively, for the good prognosis-signature group (n…

Read more